keyword
MENU ▼
Read by QxMD icon Read
search

Ramipril

keyword
https://www.readbyqxmd.com/read/29730176/a-comparative-study-between-hot-melt-extrusion-and-spray-drying-for-the-manufacture-of-anti-hypertension-compatible-monolithic-fixed-dose-combination-products
#1
J F Kelleher, G C Gilvary, A M Madi, D S Jones, S Li, Y Tian, A Almajaan, Z Senta-Loys, G P Andrews, A M Healy
The purpose of this work was to investigate the application of different advanced continuous processing techniques (hot melt extrusion and spray drying) to the production of fixed-dose combination (FDC) monolithic systems comprising of hydrochlorothiazide and ramipril for the treatment of hypertension. Identical FDC formulations were manufactured by the two different methods and were characterised using powder x-ray diffraction (PXRD) and modulated differential scanning calorimetry (mDSC). Drug dissolution rates were investigated using a Wood's apparatus, while physical stability was assessed on storage under controlled temperature and humidity conditions...
May 3, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29705104/low-temperature-fused-deposition-modeling-fdm-3d-printing-of-thermolabile-drugs
#2
Gayathri Kollamaram, Denise M Croker, Gavin M Walker, Alvaro Goyanes, Abdul W Basit, Simon Gaisford
Fused deposition modelling (FDM) is the most commonly investigated 3D printing technology for the manufacture of personalized medicines, however, high temperatures associated with the process limit its wider application. The objective of this study was to print low-melting and thermolabile drugs by reducing the FDM printing temperature. Two immediate release polymers, Kollidon VA64 and Kollidon 12PF were investigated as potential candidates for low-temperature FDM printing. Ramipril was used as the model low melting temperature drug (109°C); to the authors' knowledge this is the lowest melting point drug investigated to date by FDM printing...
April 26, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29697397/pathomorphology-of-the-myocardium-kidney-and-liver-in-spontaneously-hypertensive-rats-treated-with-short-and-long-term-use-ramipril-and-candesartan
#3
A Maruschak, E Shorikov, I Timofiichuk, I Davydenko, K Slobodyan
Choosing a method of treating arterial hypertension remains an urgent problem today. For effective therapy, it is necessary to select hypotensive drugs that not only effectively reduce the pressure, but also contribute to the restoration of the structure of tissues sensitive to oscillations of arterial pressure. The purpose of this study was to conduct a comparative analysis of the effect of angiotensin 2-candesartan receptor antagonist and angiotensin converting factor ramipril on pathomorphological changes in the myocardium, kidney, and liver in SHR lines that received treatment for 7 days (short) and 21 days (prolonged therapy ) The study was conducted on 20 spontaneously hypertensive rats with a mass of 248...
March 2018: Georgian Medical News
https://www.readbyqxmd.com/read/29691148/angiotensin-receptor-blocker-vs-ace-inhibitor-effects-on-hdl-functionality-in-patients-on-maintenance-hemodialysis
#4
R Kaseda, Y Tsuchida, J L Gamboa, J Zhong, L Zhang, H Yang, A Dikalova, A Bian, S Davies, A F Fogo, M F Linton, N J Brown, T A Ikizler, V Kon
BACKGROUND AND AIMS: Angiotensin receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEI) reduce cardiovascular events in the general population. Maintenance hemodialysis (MHD) patients are at high cardiovascular risk but few studies have directly addressed the comparative efficacy of these drugs. MHD disrupts the normally atheroprotective actions of high density lipoprotein (HDL), therefore, we compared ACEI or ARB treatment on HDL functions in MHD. METHODS AND RESULTS: HDL was isolated at the starting point (pre) and 3-6 months later (post) in 30 MHD randomly assigned to placebo, ramipril or valsartan...
March 8, 2018: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29667144/efficacy-and-safety-of-zofenopril-versus-ramipril-in-the-treatment-of-myocardial-infarction-and-heart-failure-a-review-of-the-published-and-unpublished-data-of-the-randomized-double-blind-smile-4-study
#5
REVIEW
Claudio Borghi, Stefano Omboni, Salvatore Novo, Dragos Vinereanu, Giuseppe Ambrosio, Ettore Ambrosioni
Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA)...
April 17, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29663195/which-target-blood-pressure-in-year-2018-evidence-from-recent-clinical-trials
#6
REVIEW
Sondre Heimark, Julian E Mariampillai, Krzysztof Narkiewicz, Peter M Nilsson, Sverre E Kjeldsen
The Systolic Blood Pressure Intervention Trial (SPRINT) suggested a favourable effect of lowering blood pressure to < 120/80 mmHg in high-risk hypertensive patients; however, new American guidelines in 2017 have not followed SPRINT but lowered its recommended treatment target to < 130/80 mmHg. We aimed to review the latest research from large randomised controlled trials and observational analyses in order to investigate the evidence for new treatment targets. We assessed recent data from the Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD) study, the International Verapamil-Trandolapril Study (INVEST), the Telmisartan, Ramipril or Both in Patients at High Risk for Vascular Events trial (ONTARGET)/the Telmisartan Randomised AssessmenNt Study in aCE iNtolerant participants with cardiovascular Disease (TRANSCEND) study and The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study...
April 16, 2018: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/29601411/antihypertensive-drug-use-in-resistant-and-nonresistant-hypertension-and-in-controlled-and-uncontrolled-resistant-hypertension
#7
Alejandro de la Sierra, Pedro Armario, Anna Oliveras, José R Banegas, Manuel Gorostidi, Ernest Vinyoles, Juan J de la Cruz, Julián Segura, Luis M Ruilope
BACKGROUND AND AIM: Treatment-resistant hypertension (TRH) is associated with particular clinical features, nonadherence, and suboptimal treatment. We assessed possible associations of antihypertensive drug classes, specific agents inside each class, and types of combinations, with the presence of non-TRH vs. TRH, and with controlled vs. uncontrolled TRH. METHODS: Comparisons were done in 14 264 patients treated with three drugs (non-TRH: 2988; TRH: 11 276) and in 6974 treated with at least four drugs (controlled TRH: 1383; uncontrolled TRH: 5591)...
March 29, 2018: Journal of Hypertension
https://www.readbyqxmd.com/read/29574980/blockade-of-the-renin-angiotensin-aldosterone-system-in-patients-with-arrhythmogenic-right-ventricular-dysplasia-a-double-blind-multicenter-prospective-randomized-genotype-driven-study-brave-study
#8
Elodie Morel, Ab Waheed Manati, Patrice Nony, Delphine Maucort-Boulch, Francis Bessière, Xu Cai, Timothee Besseyre des Horts, Alexandre Janin, Adrien Moreau, Phillippe Chevalier
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular arrhythmia. Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia. Thus, there is no validated treatment that will prevent the deterioration of RV function in patients with ARVD. The aim of the BRAVE study is to evaluate the effect of ramipril, an angiotensin-converting enzyme inhibitor, on ventricular myocardial remodeling and arrhythmia burden in patients with ARVD...
March 25, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29540234/stroke-minimization-through-additive-anti-atherosclerotic-agents-in-routine-treatment-smaart-study-protocol-for-a-randomized-controlled-trial
#9
Fred Stephen Sarfo, Osei Sarfo-Kantanka, Sheila Adamu, Vida Obese, Jennifer Voeks, Raelle Tagge, Vipin Sethi, Bruce Ovbiagele
BACKGROUND: There is an unprecedented rise in the prevalence of stroke in sub-Saharan Africa (SSA). Secondary prevention guidelines recommend that antihypertensive, statin and antiplatelet therapy be initiated promptly after ischemic stroke and adhered to in a persistent fashion to achieve optimal vascular-risk reduction. However, these goals are seldom realized in routine clinical care settings in SSA due to logistical challenges. We seek to assess whether a polypill containing fixed doses of three antihypertensive agents, a statin and antiplatelet therapy taken once daily per os for 12 months among recent stroke survivors would result in carotid intimal thickness regression compared with usual care (UC)...
March 14, 2018: Trials
https://www.readbyqxmd.com/read/29525675/reduction-in-nitric-oxide-bioavailability-shifts-serum-lipid-content-towards-atherogenic-lipoprotein-in-rats
#10
Esther Oluwasola Aluko, Temidayo Olutayo Omobowale, Ademola Adetokunbo Oyagbemi, Olumuyiwa Abiola Adejumobi, Temitayo Olabisi Ajibade, Adesoji Adedipe Fasanmade
Nitric oxide (NO) is major endothelial relaxing factor and reduction in its bioavailabilty has been linked to hypertension. Furthermore, high lipid content is a strong risk factor predisposing to cardiovascular diseases. The principal focus of this study was to investigate the effect of blockade of nitric oxide synthase (NOS) on serum lipid content in rats. Male Wistar rats (150-170 g, n = 15) were randomly divided into two groups designated control (n = 5), and L-Name group (n = 10) and were gavage with distilled water and 60 mg/kg of L-NAME respectively daily for three weeks...
May 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29463869/angiotensin-converting-enzyme-inhibitor-reduces-scar-formation-by-inhibiting-both-canonical-and-noncanonical-tgf-%C3%AE-1-pathways
#11
Qing-Qing Fang, Xiao-Feng Wang, Wan-Yi Zhao, Shi-Li Ding, Bang-Hui Shi, Ying Xia, Hu Yang, Li-Hong Wu, Cai-Yun Li, Wei-Qiang Tan
Angiotensin-converting enzyme inhibitors (ACEIs) can improve the fibrotic processes in many internal organs. Recent studies have shown a relationship between ACEI with cutaneous scar formation, although it has not been confirmed, and the underlying mechanism is unclear. In this study, we cultured mouse NIH 3T3 fibroblasts with different concentrations of ACEI. We measured cell proliferation with a Cell Counting Kit-8 and collagen expression with a Sirius Red Collagen Detection Kit. Flow cytometry and western blotting were used to detect transforming growth factor β1 (TGF-β1) signaling...
February 20, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29457348/fixed-dose-vs-free-dose-combinations-for-the-management-of-hypertension-an-analysis-of-81-958-patients
#12
Peter Bramlage, Stefanie Schmidt, Helen Sims
Fixed-dose combinations (FDC) have been developed to reduce the pill burden for hypertensive patients. Data on fixed-dose or free-dose (freeDC) ramipril/amlodipine (R/A) or candesartan/amlodipine (C/A) combination treatment initiation were assessed. 71 463 patients were prescribed R/A and 10 495 C/A. For both R/A and C/A, FDC patients were younger (both P < .001) and less comorbid. Prior MI (OR: 0.61 and 0.60), prior stroke (OR: 0.68 and 0.70) and CHD (OR: 0.68 and 0.64) were negatively associated with FDC use, whereas hyperlipidemia was positively associated (OR: 1...
April 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29440218/impact-of-renin-angiotensin-system-inhibitors-on-clinical-outcomes-and-ventricular-remodelling-after-transcatheter-aortic-valve-implantation-rationale-and-design-of-the-rastavi-randomised-multicentre-study
#13
Ignacio J Amat-Santos, Pablo Catalá, Felipe Diez Del Hoyo, Jose A Fernandez-Diaz, Juan H Alonso-Briales, María Del Trigo, Ander Regueiro, Pablo Juan-Salvadores, Vicenç Serra, Enrique Gutierrez-Ibanes, Antonio J Muñoz-García, Luis Nombela-Franco, Manel Sabate, Victor A Jimenez-Diaz, Bruno García Del Blanco, Javier López, Luis H Varela-Falcón, Teresa Sevilla, Roman Arnold, Ana Revilla, J Alberto San Roman
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) as a treatment in severe aortic stenosis (AS) is an excellent alternative to conventional surgical replacement. However, long-term outcomes are not benign. Renin-angiotensin system (RAS) blockade has shown benefit in terms of adverse remodelling in severe AS and after surgical replacement. METHODS AND ANALYSIS: The RAS blockade after TAVI (RASTAVI) trial aims to detect if there is a benefit in clinical outcomes and ventricular remodelling with this therapeutic strategy following the TAVI procedure...
February 13, 2018: BMJ Open
https://www.readbyqxmd.com/read/29428872/the-win-ratio-approach-did-not-alter-study-conclusions-and-may-mitigate-concerns-regarding-unequal-composite-endpoints-in-kidney-transplant-trials
#14
Nicholas A Fergusson, Tim Ramsay, Michaël Chassé, Shane W English, Greg A Knoll
OBJECTIVE: Determine the impact of using the win ratio approach and investigate whether this approach alters the interpretations or conclusions of a randomized trial in kidney transplantation. STUDY DESIGN AND SETTING: We present an application of the win ratio approach in a kidney transplant trial that assessed the clinical effectiveness of ramipril treatment versus placebo. The primary composite outcome included the time to death, kidney transplant failure, or doubling of serum creatinine...
February 8, 2018: Journal of Clinical Epidemiology
https://www.readbyqxmd.com/read/29409092/-gallop-in-the-routineergometrie-only-chore-or-diagnostic-challenge
#15
Stephan Knöchner, K Kronberg, U Schumann
ANAMNESIS:  A 47-year-old recreational sportsman showed in a routine ergometry polymorphic ventricular extrasystoles with good physical performance. INVESTIGATIONS:  In resting ECG impressed ventricular extrasystoles (VES) predominantly right-hand-block-like with superior axis, a long-term ECG yielded up to 100 VES per hour. Echocardiographically imposing 4 - 5 trabeculae, feathered, reticular structures apically in the left and lower in the right ventricle...
February 2018: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29389738/effects-of-angiotensin-converting-enzyme-inhibition-and-alpha-1-adrenergic-receptor-blockade-on-inflammation-and-hemostasis-in-human-hypertension
#16
Mikael Ekholm, Andreas Jekell, N Håkan Wallén, Bruna Gigante, Thomas Kahan
Drugs blocking the renin-angiotensin-aldosterone system may offer benefit on endothelial function, inflammation, and hemostasis in addition to the effects of reducing blood pressure. We examined the contribution of the angiotensin-converting enzyme inhibitor ramipril and the alpha 1-adrenergic receptor blocker doxazosin on blood pressure and on markers of inflammation and hemostasis in 59 individuals with mild-to-moderate hypertension randomized to receive double-blind ramipril 10 mg od or doxazosin 8 mg od for 12 weeks...
April 2018: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/29325596/late-normal-tissue-response-in-the-rat-spinal-cord-after-carbon-ion-irradiation
#17
Maria Saager, Peter Peschke, Thomas Welzel, Lifi Huang, Stephan Brons, Rebecca Grün, Michael Scholz, Jürgen Debus, Christian P Karger
BACKGROUND: The present work summarizes the research activities on radiation-induced late effects in the rat spinal cord carried out within the "clinical research group ion beam therapy" funded by the German Research Foundation (DFG, KFO 214). METHODS AND MATERIALS: Dose-response curves for the endpoint radiation-induced myelopathy were determined at 6 different positions (LET 16-99 keV/μm) within a 6 cm spread-out Bragg peak using either 1, 2 or 6 fractions of carbon ions...
January 11, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29311704/clinical-efficacy-of-african-traditional-medicines-in-hypertension-a-randomized-controlled-trial-with-combretum-micranthum-and-hibiscus-sabdariffa
#18
Sidy Mohamed Seck, Dominique Doupa, Diatou Guéye Dia, ElHadji Assane Diop, Denis-Luc Ardiet, Renata Campos Nogueira, Bertrand Graz, Boucar Diouf
Medicinal plants are widely used as a first-line therapy for hypertension, often without comparative clinical data. A prospective, randomized controlled trial was conducted to assess efficacy of Combretum micranthum (kinkeliba) and Hibiscus sabdariffa (bissap), in the galenic form of capsules of plant powder, on blood pressure in adult patients with non-complicated hypertension ( > 140/90 mm Hg). One hundred and twenty five patients were randomly allocated into group 1 (kinkeliba leaves 190 mg × 2/day), or group 2 (bissap calyx 320 mg × 2/day), or group 3 (ramipril 5 mg /day) during four consecutive weeks...
December 2017: Journal of Human Hypertension
https://www.readbyqxmd.com/read/29159410/use-of-health-care-databases-to-support-supplemental-indications-of-approved-medications
#19
Michael Fralick, Aaron S Kesselheim, Jerry Avorn, Sebastian Schneeweiss
Importance: Manufacturers of US Food and Drug Administration-approved prescription drugs often apply for additional indications based on randomized clinical trials. Real-world database analyses on a medication's use and outcomes in routine settings of care might help to inform decision making regarding such supplemental indications. Objective: To examine whether longitudinal data from a health care database can support the results of a randomized clinical trial that led to a supplemental indication for telmisartan...
January 1, 2018: JAMA Internal Medicine
https://www.readbyqxmd.com/read/29134498/vasoplegic-shock-treated-with-methylene-blue-complicated-by-severe-serotonin-syndrome
#20
Betty S Chan, Therese Becker, Angela L Chiew, Ahmed M Abdalla, Tom A Robertson, Xin Liu, Michael S Roberts, Nicholas A Buckley
INTRODUCTION: Management of severe vasoplegic shock in overdose can be very challenging. We describe a case of severe refractory vasodilatory shock in poisoning where methylene blue (MB) was used with success. However, the patient subsequently developed severe Serotonin Syndrome (SS) as a result of an interaction between serotonergic drugs and MB. CASE REPORT: A 15-year-old male developed severe vasoplegic shock 1.5 hours after overdosing on several different medications including quetiapine slow release, quetiapine immediate release, desvenlafaxine slow release, venlafaxine, amlodipine, ramipril, fluoxetine, promethazine and lithium...
March 2018: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
keyword
keyword
55573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"